Core Insights - Regentis Biomaterials Ltd. is expanding its U.S. clinical site network to enhance its infrastructure for ongoing and future clinical programs [1] - The company has surpassed 50% patient enrollment in its pivotal Phase III study of GelrinC® for knee cartilage repair [1] - GelrinC is positioned to transform the cartilage repair market with its off-the-shelf regenerative products [1] Company Developments - The expansion of clinical sites is expected to accelerate patient enrollment in the ongoing Phase III study [1] - The new sites will also support future clinical programs beyond the current study [1] Industry Impact - GelrinC is anticipated to significantly impact the cartilage repair market by providing innovative regenerative solutions [1]

Core Insights - GelrinC-treated patients showed layered cartilage architecture similar to native hyaline cartilage, indicating true biological cartilage regeneration rather than just defect filling [1] - GelrinC limits fibrotic tissue overgrowth, which supports smoother joint motion and preserves natural biomechanics [1] Company Overview - Regentis Biomaterials Ltd. is a regenerative medicine company focused on innovative tissue repair solutions [1] - The company announced new long-term imaging data from a completed European clinical trial of GelrinC® [1] Clinical Trial Results - The clinical trial demonstrated that regenerated cartilage exhibits internal structural organization closely resembling healthy, native hyaline cartilage [1]